Prime links changes in adherence rates with total cost of care

September 1, 2020

Each step up in adherence links to a step down in total cost of care

Star Ratings are tied to adherence rates and specific chronic conditions. Prime wanted to understand more about the association between adherence rates and total cost of care for Star categories. Because of Prime’s connection to Blue Plans, Prime has integrated medical and pharmacy claims data and could track adherence rates to total cost of care.

Starting with a large Medicare population (over 560,000 members across 20 contracts) gave us strong cohorts to work with after applying analytic criteria. We looked at two years of data.

This study is rich with data you will not find anywhere else. It shows a statistically significant association between increasing adherence within Medicare Star Rating drug categories and lower total cost of care, as well as lower odds of hospitalizations and emergency department visits.

Every increase in adherence was associated with a decrease in total cost of care.

Each one percentage point adherence increase was associated with a cost-of-care decrease of $21 to $46 per patient per year. The specific dollar amount cost decrease varied by drug disease category. The most adherent individuals had lower annual total cost of care of between $1,353 and $3,713, depending on the drug disease category, compared to the least adherent individuals.

Findings are limited by potential healthy adherer effect.

Read more.

Is Medicare Star Category Medication Adherence Associated with Lower Total Cost of Care and Medical Events? (Spring 2020)

Related news

Perspectives

September 14, 2023

Cheers to 20 years and another amazing Specialty Summit!

The 20th annual Specialty Summit hosted by Prime and Magellan Rx returned to…

Perspectives

September 8, 2023

October 2023 decisions expected from the FDA

At Prime Therapeutics (Prime), we’ve positioned ourselves to best prepare our clients to…

Perspectives

August 28, 2023

Specialty Drug Pipeline Monthly Update: August 2023

This monthly pipeline wrap-up provides a review of newly approved specialty drugs, recent…